Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

In spite of the successful use of monoclonal antibodies (mAbs) in clinic for tumor treatment,
their applications are still hampered in therapeutic development due to limitations, such as …

The nuclear medicine field has seen a rapid expansion of academic and commercial interest
in developing artificial intelligence (AI) algorithms. Users and developers can avoid some of …

68Ga-NOTA-WL12 is a peptide-based PET imaging agent. We conducted a first-in-human
study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation …

Better biomarkers are needed to predict treatment outcome in non–small cell lung cancer
(NSCLC) patients treated with anti–programmed death-1/programmed death-ligand 1 (PD …

For treatment and diagnosis of cancer, antibodies have proven their value and now serve as
a first line of therapy for certain cancers. A unique class of antibody fragments called …

Camelidae derived single-domain antibodies (sdAbs), commonly known as nanobodies
(Nbs), are the smallest antibody fragments with full antigen-binding capacity. Owing to their …

Simple Summary PD-L1 plays a crucial role in the immune responses against cancer. Only
around 30% of cancer patients respond to an anti-PD-L1 immune checkpoint inhibitor …

Immune checkpoint inhibitor (ICI) therapy has emerged as a major treatment option for a
variety of cancers. Among the immune checkpoints addressed, the programmed death …